Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 50 results for "Cr24"

CREE : Patent Application Titled "Lighting Apparatus and Metho...

By a News Reporter-Staff News Editor at Electronics Newsweekly -- According to news reporting originating from Washington, D.C. , by VerticalNews journalists, a patent application by the inventors Gilliom, Michael Burbank ( Raleigh, NC ); Keiter, ... 4 Traders, 2 weeks ago

10 images for Cr24

Cape Gazette, 2 weeks ago
Cape Gazette, 2 weeks ago
Cape Gazette, 2 weeks ago
Cape Gazette, 2 weeks ago
Cape Gazette, 2 weeks ago
Cape Gazette, 2 weeks ago
Cape Gazette, 2 weeks ago
Cape Gazette, 2 weeks ago
Cape Gazette, 2 weeks ago
Cape Gazette, 2 weeks ago

Stock Market Special Report by www.epicresearch.co - 1st October 2014

Asian shares got off on the back foot on Wednesday as continued civil unrest in Hong Kong sapped confidence, while the dollar index was in sight of a four-year high after marking its best quarterly gain in six years. P { margin-bottom: 0.21cm; ...
 Press Release Ping3 weeks ago

FTIL opposes merger of NSEL with itself

It also informed that NSEL has recovered more than Rs 360 cr from 24 defaulters and same has been distributed proportionately amongst the investors. NEW DELHI: FTIL today opposed the merger of scam-hit NSEL with itself as proposed by regulator FMC for speedy ...
 Economic Times1 month ago

Financial Technologies India Ltd opposes merger of National Spot Exchange Ltd with itself

It also informed that NSEL has recovered more than Rs 360 cr from 24 defaulters and same has been distributed proportionately amongst the investors. NEW DELHI: FTIL today opposed the merger of scam-hit NSEL with itself as proposed by regulator FMC for speedy ...
 Economic Times1 month ago
Emirates Week

Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate

/Business Wire SUMMIT, N.J. Thursday, August 21st 2014 Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin ...
 Emirates Week2 months ago CELGENE : Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate  4 Traders2 months ago
[x]  

《臨床腫瘤學雜誌》發表口服REVLIMID聯合標準R-CHOP治療彌漫性大B細胞淋巴瘤患者的臨床研究結果,總緩解率達到98%,完全緩解率達到80%

紐澤西州桑米--( BUSINESS WIRE )--(美國商業資訊) -- Celgene Corporation (NASDAQ:CELG)今天宣布,一項評估REVLIMID®(lenalidomide)聯合rituximab、cyclophosphamide、doxorubicin ...
 Business Wire2 months ago 《临床肿瘤学杂志》发表口服REVLIMID联合标准R-CHOP治疗弥漫大B细胞淋巴瘤患者的临床研究结果,总缓解率达到98%,完全缓解率达到80%  Business Wire2 months ago

63 rise in molestation cases on Mumbai local trains

The city's local trains continue to be unsafe for women commuters, with a 63% rise in cases of molestation and misbehaviour in 2014 (between January and July), as compared with the same period last year. Even with the alarming rise, however, the ...
 Hindustan Times2 months ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less